We investigated the effects of Goshajinkigan (GJG), a Chinese herbal medicine, on insulin sensitivity in patients with type 2 diabetes using the homeostasis model assessment of insulin resistance (HOMA-R) and the euglycemic insulin clamp procedure. Daily oral administration of GJG (7.5 g/day) was performed for 1 month in 71 type 2 diabetes patients: the GJG treatment group. HOMA-Rs were calculated before and after 1 month of GJG treatment and compared with those of 44 controls who were matched in terms of sex, age, body mass index (BMI) and HbA1c levels with the experimental group. In 64 patients out of the GJG treatment group, HOMA-R was calculated 1 month after discontinuation of treatment. In addition, euglycemic clamp was conducted in eight patients before and after the GJG treatment. HOMA-R was 4.78+/-0.37 (means+/-S.E.) before GJG treatment and significantly decreased to 4.02+/-0.25 after GJG treatment (P=0.019). No significant change was observed in the control group. HOMA-R returned to the pre-treatment level (P=0.018) 1 month after GJG treatment discontinuation. Glucose infusion rates and metabolic clearance rates determined by the high-dose euglycemic clamp increased after 1 month of GJG treatment (from 9.6+/-1.1 to 11.1+/-0.7 mg/kg/min, P=0.045 and from 7.9+/-0.8 to 9.1+/-0.8 ml/kg/min, P=0.046, respectively). These results indicate that GJG administration might be useful for improving insulin resistance in patients with type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabres.2004.11.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite.
N Engl J Med
November 2024
From Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden (O.A.C.L., B.M.D.F-.F., J.P.R.K., G.V.T.R., J.J.J., S.C.C.-M., F.J.A.G., H.M.B.-R., E.I., E.C., E.W., E.L.H., R.M., C.J.J., M.R.), and the Department of Medical Microbiology, Radboud University Medical Center, Nijmegen (G.-J.G., M.V.-B., W.G., T.R.S., B.G.M., T.B., M.B.B.M.) - both in the Netherlands.
Background: Currently licensed and approved malaria subunit vaccines provide modest, short-lived protection against malaria. Immunization with live-attenuated malaria parasites is an alternative vaccination strategy that has potential to improve protection.
Methods: We conducted a double-blind, controlled clinical trial to evaluate the safety, side-effect profile, and efficacy of immunization, by means of mosquito bites, with a second-generation genetically attenuated parasite (GA2) - a single knockout NF54 parasite (sporozoite form) with extended development into the liver stage.
Oral Anticoagulation and Factor VIII Replacement Therapy in Patients With Hemophilia Undergoing Pulsed-Field or Radiofrequency Catheter Ablation for Atrial Fibrillation.
Circ Arrhythm Electrophysiol
October 2024
Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX (S.M., P.G.T., V.M.L.F., C.G., B.M., A.Q.M., J.A., M.B., G.J.G., J.D.B., R.H., A.A.-A., A.N.).
Effectiveness of the Traditional Japanese Medicine Goshajinkigan in Preventing Paclitaxel-Induced Peripheral Neuropathy: A Multicenter Randomized Comparative Trial.
Integr Cancer Ther
September 2024
Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Article Synopsis
- Development of chemotherapy-induced peripheral neuropathy (CIPN) can complicate cancer treatment, leading to dose reductions or stopping therapy; Goshajinkigan (GJG), a traditional Japanese medicine, may help reduce these symptoms.
- A study with 55 ovarian cancer patients tested two groups: one started GJG after experiencing grade 2 neuropathy, while the other took it a week before chemotherapy; the main goals were to assess sensory neuropathy severity and pain levels.
- Results showed that patients starting GJG early (Group B) had fewer pain complaints, lower reliance on pain medications, and less persistent neuropathy six months later, suggesting that preventive use of GJG could be beneficial, but more research is needed for confirmation
Randomized, placebo-controlled study on the effects of intravenous GSK3858279 (anti-CCL17) on a battery of evoked pain tests in healthy participants.
Clin Transl Sci
September 2024
Centre for Human Drug Research, Leiden, The Netherlands.
Article Synopsis
- CCL17 is a protein that affects inflammation and pain, and GSK3858279 is a new antibody that targets it to help with pain relief.
- A study was done on healthy adult males to see if GSK3858279 could reduce pain better than a placebo (a fake treatment).
- The results showed that there wasn’t a big difference in pain relief between GSK3858279 and the placebo, but it was safe and didn’t cause serious problems for the participants.
A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol.
Respir Investig
September 2024
Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, 700-8558, Japan.
Background: Paclitaxel (PTX) is an essential cytotoxic anticancer agent and a standard treatment regimen component for various malignant tumors, including advanced unresectable non-small cell lung cancer, thymic cancer, and primary unknown cancers. However, chemotherapy-induced peripheral neuropathy (CIPN) caused by PTX is a significant adverse event that may lead to chemotherapy discontinuation and deterioration of the quality of life (QOL). Although treatment modalities such as goshajinkigan (GJG), pregabalin, and duloxetine are empirically utilized for CIPN, there is no established evidence for an agent as a preventive measure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!